Keros Therapeutics, Inc. Variable Lease, Cost
Keros Therapeutics, Inc. (KROS) reported Variable Lease, Cost of $2.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-04
- Keros Therapeutics, Inc. variable lease, cost for the quarter ending 2024-12-31 was $525.00K, a 13.88% increase year-over-year.
- Keros Therapeutics, Inc. variable lease, cost for the quarter ending 2023-12-31 was $461.00K, a 738.18% increase year-over-year.
- Keros Therapeutics, Inc. variable lease, cost for the quarter ending 2022-12-31 was $55.00K, a 81.36% decline year-over-year.
- Keros Therapeutics, Inc. variable lease, cost for the quarter ending 2021-12-31 was $295.00K.
- Keros Therapeutics, Inc. variable lease, cost for fiscal 2025 was $2.05M, a 31.72% increase from fiscal 2024.
- Keros Therapeutics, Inc. variable lease, cost for fiscal 2024 was $1.55M, a 18.00% increase from fiscal 2023.
- Keros Therapeutics, Inc. variable lease, cost for fiscal 2023 was $1.32M, a 137.30% increase from fiscal 2022.
- Keros Therapeutics, Inc. variable lease, cost for fiscal 2022 was $555.00K, a 88.14% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 9 month as first filed | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $2.05M 10-K · filed 2026-03-04 | ||||
| 2024-12-31 | $525.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.55M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $1.03M 10-Q · filed 2024-11-06 | ||||
| 2023-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.32M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $856.00K 10-Q · filed 2024-11-06 | $900.00K 10-Q · filed 2023-11-06 | |||
| 2022-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $555.00K 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $295.00K derived: sum of 2 quarters · filed 2024-02-28 | $295.00K 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |